{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:20:04Z","timestamp":1793262004166,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023954","name":"Sociedad Espa\u00f1ola de Arteriosclerosis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.arteri.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T20:24:07Z","timestamp":1733430247000},"page":"S24-S30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Eficacia, beneficio y seguridad de inclisiran"],"prefix":"10.1016","volume":"36","author":[{"given":"Jos\u00e9","family":"L\u00f3pez-Miranda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2024.07.003_bib0125","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2024.07.003_bib0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.07.003_bib0140","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","article-title":"Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial","volume":"4","author":"Ray","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/dc18-1491","article-title":"Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial","volume":"42","author":"Leiter","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arteri.2024.07.003_bib0150","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.07.003_bib0155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.122.063460","article-title":"Efficacy Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial","volume":"149","author":"Raal","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.07.003_bib0160","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.119.044431","article-title":"Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin\/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study","volume":"141","author":"Hovingh","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.07.003_bib0165","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.07.003_bib0170","doi-asserted-by":"crossref","first-page":"117354","DOI":"10.1016\/j.atherosclerosis.2023.117354","article-title":"Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials","volume":"386","author":"Landmesser","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.07.003_bib0175","doi-asserted-by":"crossref","first-page":"100503","DOI":"10.1016\/j.ajpc.2023.100503","article-title":"Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11","volume":"14","author":"Koenig","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0180","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s10557-022-07413-0","article-title":"Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9 ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials","volume":"38","author":"Koenig","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.arteri.2024.07.003_bib0185","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: The ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.07.003_bib0190","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An \u201cInclisiran First\u201d Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2024.05.003","article-title":"Lipid-lowering therapy with inclisiran in the real-world setting: Initial data from a national health care service","author":"Naoum","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0200","first-page":"9","article-title":"Lipid lowering with inclisiran: A real-world single-centre experience","author":"Padam","year":"2022","journal-title":"Open Heart."},{"key":"10.1016\/j.arteri.2024.07.003_bib0205","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00392-023-02247-8","article-title":"High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany","volume":"112","author":"Makhmudova","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0210","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacl.2023.09.005","article-title":"First clinical experiences with inclisiran in a real-world setting","volume":"17","author":"Mulder","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: A patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.07.003_bib0220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0225","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","article-title":"Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis","volume":"77","author":"Wright","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","article-title":"Effects of Renal Impairment on the Pharmacokinetics Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies","volume":"95","author":"Wright","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.arteri.2024.07.003_bib0235","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","article-title":"Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment","volume":"16","author":"Kallend","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0240","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.07.003_bib0245","doi-asserted-by":"crossref","unstructured":"Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, et al. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024;120:1400-10.","DOI":"10.1093\/cvr\/cvae109"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916824000767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916824000767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T20:55:48Z","timestamp":1733432148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916824000767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"alternative-id":["S0214916824000767"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2024.07.003","relation":{},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eficacia, beneficio y seguridad de inclisiran","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Arteriosclerosis.","name":"copyright","label":"Copyright"}]}}